4//SEC Filing
Caballa Susan 4
Accession 0001181431-12-066889
CIK 0001267602other
Filed
Dec 20, 7:00 PM ET
Accepted
Dec 21, 6:24 PM ET
Size
7.7 KB
Accession
0001181431-12-066889
Insider Transaction Report
Form 4
Caballa Susan
SEE REMARKS
Transactions
- Award
Employee Stock Option (Right to Buy)
2012-12-19+90,000→ 90,000 totalExercise: $1.66Exp: 2022-12-18→ Common Stock (90,000 underlying) - Award
Employee Stock Option (Right to Buy)
2012-12-19+35,000→ 35,000 totalExercise: $1.66Exp: 2022-12-18→ Common Stock (35,000 underlying)
Footnotes (2)
- [F1]This option shall vest in forty-eight equal monthly installments beginning on January 19, 2013, provided Reporting Person remains continuously employed by the Issuer through each vesting period.
- [F2]This option shall become exercisable if and only if on or before June 30, 2013 the United Kingdom's National Institute for Health and Clinical Excellence recommends ILUVIEN(R) for the treatment of diabetic macular edema, in which case this option shall vest in forty-eight equal monthly installments beginning on January 19, 2013, provided Reporting Person remains continuously employed by the Issuer through each vesting period.
Documents
Issuer
ALIMERA SCIENCES INC
CIK 0001267602
Entity typeother
Related Parties
1- filerCIK 0001489530
Filing Metadata
- Form type
- 4
- Filed
- Dec 20, 7:00 PM ET
- Accepted
- Dec 21, 6:24 PM ET
- Size
- 7.7 KB